Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%
Market cap
$11.7B
P/E
234×
Fwd P/E
112×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
1.99% 2.51% 2.40% 0.08%

+8 more TTM periods

Piotroski F-Score
7 7 6 6
ROA
1.42% 1.78% 1.69% 0.06%
ROIC
2.18% 2.16% 1.83% 0.03%
Return on Tangible Assets
3.36% 4.25% 4.12% 0.15%
Average Days of Receivables
73.32 72.47 78.41 76.81
Free Cash Flow per Share
1.96 1.86 1.63 1.87
Free Cash Flow
110.35 104.66 91.93 105.23
Capital Expenditures
(24.51) (26.05) (25.49) (25.66)
Other line items
Cash ROIC
3.18% 3.05% 2.69% 3.12%
Accounts Receivable Turnover
4.99 5.11 5.04 5.09
Accounts Payable Turnover
12.40 11.70 11.33 15.13
Inventory Turnover
2.13 2.17 2.25 2.24
Average Days of Payables
33.24 35.12 31.12 27.96
Days of Inventory on Hand
186.65 181.65 176.75 152.32
Tax Rate
(0.20) (0.09) (0.22) (0.63)
Research and Development Expense of Revenue
7.26% 7.40% 7.34% 7.34%
Selling, General and Administrative Expense of Revenue
38.47% 38.82% 39.35% 38.95%
Share Based Compensation of Revenue
4.24% 4.41% 4.42% 4.38%
Interest Coverage
2.92 2.95 2.56 0.04
Operating CF/Net income
3.25 2.54 2.40 75.31
Depreciation/Fixed assets
0.58 0.56 0.51 0.49
Capex/Depreciation
(0.25) (0.27) (0.27) (0.27)
Revenue per Share
13.92 13.55 13.13 12.58
Operating CF per Share
2.39 2.32 2.09 2.33
Capex per Share
(0.43) (0.46) (0.45) (0.46)
Capex to Sales
0.03 0.03 0.03 0.04

Fold the line items

Columns are period end dates